Navigation Links
Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
Date:1/24/2008

New data supports recent IND and forms foundation for upcoming clinical

programs

PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the Diabetes Mellitus, Insulin Action and Resistance Keystone Symposia in Breckenridge, Colorado.

Genaera research scientists concluded that treatment with MSI-1436 leads to marked improvement in glucose tolerance and lowers plasma insulin levels in diet-induced obese (DIO) mice and improves fasting blood glucose and glucose tolerance in hyperglycemic animal models, and that these effects are maintained over time. In one study, the researchers reported that four weekly treatments of MSI-1436 administered to DIO mice resulted in significant reductions in plasma insulin levels. Additionally, hyperglycemic (Ob/Ob) mice treated with weekly doses of MSI-1436 for 122 days demonstrated that the significant improvements in glucose tolerance, as measured by oral glucose tolerance testing can be sustained during long periods of therapy. The scientists concluded that the anti-diabetic properties of MSI-1436 included improved insulin sensitivity, lowering of plasma insulin levels and durable improvements in fasting blood glucose and glucose tolerance.

"This encouraging preclinical work continues to provide strong basic science support and direction for our efforts to explore MSI-1436 as a therapy for type 2 diabetes," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "With our recent investigational new drug (IND) filing for type 2 d
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. CEL-SCI Corporation Releases Letter to Shareholders
9. Alfacell Corporation to Present at UBS Global Life Sciences Conference
10. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
11. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/23/2014)... Parents and physicians concerned about an increase in adolescents, ... breathe a sigh of relief. According to a new ... worth of data from states with and without medical ... increased use among adolescents. The study is published online ... Adolescent Health . , "Any time a state ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
(Date:4/22/2014)... are small cell lung cancers (SCLC), which grow ... researchers at Virginia Commonwealth University Massey Cancer Center ... to this resistance that may lead to improved ... B-cell lymphoma 2 (Bcl-2) family proteins, which are ... function, this family of proteins can trigger a ...
(Date:4/22/2014)... scientists have found a way to block abnormal cholesterol ... atherosclerosis, the main cause of heart attacks and strokes ... condition develops when fat builds inside blood vessels over ... reducing their ability to feed oxygen-rich blood to the ... of experiments, described April 7 in the journal ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... ST. LOUIS, Aug. 18 Reliv International, Inc. (Nasdaq: ... and business tools for its independent distributors here at its 21st annual ... Highlights of the conference included: , , The ... exclusive "r( )collection" of personal care products. (See www.re ...
... Hospitals, Physicians Work Together to Cut Costs, Improve ... 18 Twelve New Jersey hospitals and their participating physicians are ... that will evaluate gainsharing as an innovative new incentive method that ... , "Rising healthcare costs are a growing burden ...
... , SUNNYVALE, Calif., Aug. 18 ... systems including the Expresso Fitness Virtual Reality Bike, announced today ... excess of $6 million from Sierra Ventures, Physic Ventures, and ... company to enhance and accelerate new features and functionality to ...
... , OKLAHOMA CITY, Aug. 18 Almost everyone ... ar a cts at some point. As more Americans ... cataract basics: risks and symptoms, tips that may delay onset, and how to ... , , August is Cataract Awareness Month, and the Oklahoma ...
... AUSTIN, Texas, Aug. 18 Almost everyone who lives a ... some point. As more Americans live into their 70s and beyond, we ... that may delay onset, and how to decide when it is time ... August is Cataract Awareness Month, and the Texas Ophthalmological Association (TOA) ...
... of polyphenols , TUESDAY, Aug. 18 (HealthDay News) -- ... is a great source of natural antioxidants, new research ... the University of Scranton, in Pennsylvania, and his team ... many common, grain-based snacks contain substantial amounts of polyphenols, ...
Cached Medicine News:Health News:Reliv International Launches New Products and Business Tools at 21st International Conference 2Health News:Reliv International Launches New Products and Business Tools at 21st International Conference 3Health News:Update: Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Expresso Fitness(R) Announces $6M Series D Funding 2Health News:Expresso Fitness(R) Announces $6M Series D Funding 3Health News:What Oklahomans Should Know About Cataract Surgery 2Health News:What Oklahomans Should Know About Cataract Surgery 3Health News:What Texans Should Know about Cataract Surgery 2Health News:What Texans Should Know about Cataract Surgery 3Health News:Antioxidants Abound in Cereals, Popcorn, Whole-Grain Snacks 2Health News:Antioxidants Abound in Cereals, Popcorn, Whole-Grain Snacks 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: